title: Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.
abstract: OBJECTIVE
  Aberrant expression of PARP-1 has been reported in various human malignancies and was involved in the progression and metastasis of cancers. However, little is known about PARP-1 expression in prostate cancer (PCa). This study aimed to investigate the expression of PARP-1 and its active polymer poly(ADP-ribose) (PAR) in PCa and benign prostatic hyperplasia (BPH) tissues from Chinese patients.
  
  
  METHODS
  The expression of PARP-1 and PAR in PCa and benign prostate hyperplasia tissues was assessed by immunohistochemistry in 78 PCa patients and 49 BPH patients. The relationship between the expression of PARP-1 or PAR and clinicopathological parameters in PCa patients was also analyzed.
  
  
  RESULTS
  Both the positive and strong positive expression rates of PARP-1 in PCa tissues were significantly higher than those in BPH tissues. Although spearman correlations analysis showed the over-expression of PARP-1 and PAR in PCa tissues was not correlated with age, serum PSA level and Gleason scores (GS), an increasing trend was observed between over-expression of PARP-1 or PAR and the PSA levels (TPSA >20 vs TPSA ≤20) or GS grade (GS ≥8 vs GS ≤6).
  
  
  CONCLUSIONS
  PARP-1 and PAR expression is markedly elevated in PCa than that in BPH tissues, which may implicate that PARP-1 and PAR are involved in the development of PCa, and the possible expansion in the use of poly(ADP-ribose) polymerase inhibitors for targeting therapy of PCa in select patients alone or combined with chemotherapy or radiation.
authors.affiliation: Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Kangda Road 1#, Haizhu District, Guangzhou, 510230, Guangdong, China, wwqwml@163.com.
authors.forename: Wenqi
authors.initials: W
authors.lastname: Wu
authors.forename: Hanliang
authors.initials: H
authors.lastname: Zhu
authors.forename: Yeping
authors.initials: Y
authors.lastname: Liang
authors.forename: Zhenzhen
authors.initials: Z
authors.lastname: Kong
authors.forename: Xiaolu
authors.initials: X
authors.lastname: Duan
authors.forename: Shujue
authors.initials: S
authors.lastname: Li
authors.forename: Zhijian
authors.initials: Z
authors.lastname: Zhao
authors.forename: Dong
authors.initials: D
authors.lastname: Yang
authors.forename: Guohua
authors.initials: G
authors.lastname: Zeng
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D002681:China; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D000071137:Poly (ADP-Ribose) Polymerase-1; D011064:Poly Adenosine Diphosphate Ribose / Q000378:metabolism*; D011065:Poly(ADP-ribose) Polymerases / Q000096:biosynthesis*; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism*
chemical_list: D011064:Poly Adenosine Diphosphate Ribose; C499320:PARP1 protein, human; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases